Blood Res.  2018 Mar;53(1):3-6. 10.5045/br.2018.53.1.3.

The role of allogeneic hematopoietic stem cell transplantation in the four P medicine era

• Morello E
• Malagola M
• Bernardi S
• Pristipino C
• Russo D

• KMID: 2414355
• DOI: http://doi.org/10.5045/br.2018.53.1.3

Abstract

No abstract available.

MeSH Terms

Hematopoietic Stem Cell Transplantation*
Hematopoietic Stem Cells*

Figure

• 

  Fig. 1 Systems medicine research studied health and diseases through the investigation of several layers of knowledge (biological, psychological, social and environmental, the so called “Omics”) and could be interpreted as an informational science in which the interpretation of a multilayer analysis could analyze the dynamic of the pathological process over time. New technologies for large-scale data analysis and a definition of a multidimensional minimal data set for everyone are under investigation to override a simple mechanistic interpretation. For these reasons “Omics” are part of the dynamic study of allogeneic transplanted patients and should be integrated with the interpretation of the connections between individual and family, society, environment and health system. This process is crucial for the personalization of the transplanted patient's care. The interaction of the several inter- and intra-individual layers over time will contribute to a new sets of complex phenotypes typical for the transplanted patient. In a few years, billions of data concerning complex phenotypes will be available for everyone. Personalization, prevention, prediction and participation are thus cornerstones of the care for such complex patients and Information Technologies will be part of this research process.

Reference

1. Hood L, Friend SH. Predictive, personalized, preventive, participatory (P4) cancer medicine. Nat Rev Clin Oncol. 2011; 8:184–187.

2. Strebhardt K, Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer. 2008; 8:473–480.

3. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science. 2000; 289:1938–1942.

4. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003; 348:994–1004.

5. Innes AJ, Milojkovic D, Apperley JF. Allogeneic transplantation for CML in the TKI era: striking the right balance. Nat Rev Clin Oncol. 2016; 13:79–91.

6. Niederwieser D, Baldomero H, Szer J, et al. Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey. Bone Marrow Transplant. 2016; 51:778–785.

7. Gratwohl A, Baldomero H, Aljurf M, et al. Hematopoietic stem cell transplantation: a global perspective. JAMA. 2010; 303:1617–1624.

8. Passweg JR, Baldomero H, Bader P, et al. Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant. 2017; 52:811–817.

9. D'Souza A, Pasquini M, Spellecy R. Is 'informed consent' an 'understood consent' in hematopoietic cell transplantation? Bone Marrow Transplant. 2015; 50:10–14.

10. ten Brink MH, Zwaveling J, Swen JJ, Bredius RG, Lankester AC, Guchelaar HJ. Personalized busulfan and treosulfan conditioning for pediatric stem cell transplantation: the role of pharmacogenetics and pharmacokinetics. Drug Discov Today. 2014; 19:1572–1586.

11. El Cheikh J, Otrock ZK, Qannus AA, Kharfan-Dabaja MA, Bazarbachi A. Risk-adapted approach to HLA-matched sibling hematopoietic cell allografting: impact of adjusting conditioning intensity and integrating post-transplant therapeutic interventions. Clin Lymphoma Myeloma Leuk. 2016; 16:304–310.

12. Malagola M, Skert C, Borlenghi E, et al. Postremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients. Cancer Med. 2016; 5:265–274.

13. Tsirigotis P, Byrne M, Schmid C, et al. Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT. Bone Marrow Transplant. 2016; 51:1431–1438.

14. Giebel S, Czyz A, Ottmann O, et al. Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosomepositive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer. 2016; 122:2941–2951.

15. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005; 106:2912–2919.

16. DeFor TE, Le C, Smith AR, Warlick ED, Bejanyan N, Weisdorf DJ. Validation of a modified comorbidity index for allogeneic hematopoietic cell transplant. Blood. 2016; 128:Suppl. abst 1167. (ASH Annual Meeting Abstracts).

17. Hashmi S, Carpenter P, Khera N, Tichelli A, Savani BN. Lost in transition: the essential need for long-term follow-up clinic for blood and marrow transplantation survivors. Biol Blood Marrow Transplant. 2015; 21:225–232.

18. Wagner EH, Davis C, Schaefer J, Von Korff M, Austin B. A survey of leading chronic disease management programs: are they consistent with the literature. Manag Care Q. 1999; 7:56–66.

19. Jacobsohn DA, Kurland BF, Pidala J, et al. Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. Blood. 2012; 120:2545–2552.

20. Rioth MJ, Warner J, Savani BN, Jagasia M. Next-generation long-term transplant clinics: improving resource utilization and the quality of care through health information technology. Bone Marrow Transplant. 2016; 51:34–40.

21. Dyer G, Gilroy N, Brown L, et al. What they want: inclusion of blood and marrow transplantation survivor preference in the development of models of care for long-term health in Sydney, Australia. Biol Blood Marrow Transplant. 2016; 22:731–743.